This page is managed by our partners. The opinions expressed and content displayed are theirs, not ours, and they do not purport to reflect the opinions or views of Aspect Health or YourDNA.com. We make no claims to their accuracy.
Transforming peoples’ lives with genetic medicines
AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including large and orphan indications, infectious disease, immune-oncology, and monogenic disorders. AGT expects to take its lead candidate for a HIV functional cure into the clinic in 2019, and is pioneering a novel immuno-oncology approach of stimulating gamma-delta (γδ) T cells to attack multiple cancers. AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine, and key patents in AGT's novel immuno-oncology approach have already been granted. AGT has developed a modified gene (patent-pending) able to express therapeutic levels of phenylalanine hydroxylase (PAH) that it is deploying, along with other proprietary AGT technologies, in pursuit of a cure for Phenylketonuria (PKU). AGT expects to begin clinical activities for PKU in 2019, and for liver cancer (AGT's first immuno-oncology therapy) in 2020.